Pharmaceuticals

Biotechnology

The 94% Question: What GSK's Jideytro Data Means for First-Line ROS1 Lung Cancer

GSK's Jideytro demonstrates a 94% response rate in first-line ROS1-positive NSCLC, with a remarkable 15% complete response rate and 100% intracranial response rate in patients with brain metastases.

Biotechnology

Breaking the Curse: How Remibrutinib's MS Win Could Rewrite the BTK Inhibitor Story

Novartis's remibrutinib has achieved what the BTK inhibitor class could not: a Phase 3 win in multiple sclerosis with no liver safety signal. Here's why this matters for the future of MS treatment.

Biotechnology

The First-Line Frontier: What Amgen's Imdelltra Phase 3 Win Means for Small Cell Lung Cancer

Amgen's Phase 3 DeLLphi-305 trial delivered a landmark overall survival win for tarlatamab in first-line extensive-stage small cell lung cancer, marking the first time a bispecific T-cell engager has demonstrated this benefit in this setting.

Biotechnology

The $12 Billion Question: What Novartis's DM1 Failure Reveals About the Limits of Acquisition-Driven Drug Development

Novartis's $12 billion acquisition of Avidity Biosciences and the subsequent failure of del-desiran in Phase 3 trials reveals critical lessons about the limits of acquisition-driven drug development in rare disease.

Pharmaceuticals

Reading the Blood: What Etcamah's Approval Means for Breast Cancer and the Liquid Biopsy Era

AstraZeneca's Etcamah became the first FDA-approved cancer therapy triggered by a blood test detecting resistance before imaging shows progression. The approval rewrites how oncologists think about treatment switching in HR-positive breast cancer.

Biotechnology

A Name for the Nameless: What Zanvastro's Approval Means for Alexander Disease and RNA Medicine

The FDA's approval of Zanvastro marks the first treatment ever approved for Alexander disease, signaling a broader shift in how RNA-targeted therapies can address ultra-rare neurological conditions.

Pharmaceuticals

The Second Wave: Why GSK's mRNA Flu Vaccine Push Could Reshape a Market Moderna Just Opened

GSK is advancing an mRNA flu vaccine that targets both hemagglutinin and neuraminidase into Phase 3, a more ambitious dual-antigen approach than Moderna's recently approved mFlusiva. Here is what the science means and why it matters.

Pharmaceuticals

Thirty Years in the Making: What the FDA's BESREMi Approval Means for Essential Thrombocythemia

The FDA's approval of BESREMi marks the first new therapy for essential thrombocythemia in nearly 30 years, signaling a shift toward disease-modifying treatments that target the molecular drivers of this rare blood cancer.

Pharmaceuticals

The Last Frontier in Cardiology: Why the Lp(a) Drug Race Could Rewrite Heart Disease Prevention

Novartis, Amgen, and Eli Lilly are racing to address Lp(a), a genetic cardiovascular risk factor affecting 1 in 5 people with no approved treatment. The first pivotal outcomes data could arrive within weeks.

Biotechnology

The Undruggable Made Druggable: What Rasonque's FDA Approval Means for Pancreatic Cancer and the RAS Era

The FDA's approval of Rasonque marks a watershed moment in oncology—the first therapy to directly target RAS, ending three decades of failed attempts to drug one of cancer's most intractable targets.

Pharmaceuticals

Fixing the Wiring: What Takeda's Orzeyful Approval Means for Narcolepsy and the Orexin Era

Takeda's FDA approval of Orzeyful marks a paradigm shift in narcolepsy treatment—the first medicine to directly target orexin deficiency rather than manage symptoms.

Biotechnology

Beyond GLP-1: Roche's $2.3B Bet on Muscle-Sparing Obesity Science

Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.